# US 2023/0058162 A1 · Multimeric coronavirus binding molecules and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058162 A1
- Document ID: US20230058162A1
- Status: Published application
- Kind: A1
- Application number: 17/386,397
- Filed: 2021-07-27
- Published: 2023-02-23
- Earliest claimed: 2020-07-27
- Applicants: IGM Biosciences, Inc.
- Inventors: Paul R. Hinton; Bruce Alan Keyt; Dean Ng; Kathy Miller; Deepal Pandya; Stephen F. Carroll
- Web page: https://patentgrep.com/patent/US20230058162A1

## CPC

- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- A61P 31/14: for RNA viruses
- A61K 39/42: viral
- A61K 2039/505: {comprising antibodies}
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing human coronavirus disease, e.g., coronavirus disease 2019 (COVID-19).

## Claims

### Claim 1

A multimeric binding molecule comprising two to six bivalent binding units or variants or fragments thereof, wherein each binding unit comprises two IgM or IgA heavy chain constant regions or multimerizing fragments or variants thereof, each associated with a binding domain, wherein three to twelve of the binding domains are identical and specifically bind to a human coronavirus, and wherein the binding molecule is more potent than a bivalent reference IgG antibody comprising two of the binding domains that specifically bind to the human coronavirus.

### Claim 2 (depends on 1)

The multimeric binding molecule of claim 1, wherein the human coronavirus is SARS-CoV, MERS-CoV, SARS-CoV-2, variants thereof, derivatives thereof, or any combination thereof.

### Claim 3 (depends on 1)

The multimeric binding molecule of claim 1, wherein the binding molecule can neutralize infectivity of the human coronavirus at a lower 50% effective concentration (EC50) than the bivalent reference IgG antibody, and wherein the EC50 is at least two-fold, at least five-fold, at least ten-fold, at least fifty-fold, at least 100-fold, at least 500-fold, or at least 1000-fold lower than the EC50 of the bivalent reference IgG antibody.

### Claim 4 (depends on 1)

The multimeric binding molecule of claim 1, wherein the binding molecule can inhibit binding of the human coronavirus to its receptor at a lower 50% inhibitory concentration (IC50) than the bivalent reference IgG antibody.

### Claim 5 (depends on 4)

The multimeric binding molecule of claim 4, wherein the human coronavirus is SARS-CoV or SARS-CoV-2 and the receptor is human angiotensin-converting enzyme 2 (ACE2), or wherein the human coronavirus is MERS-CoV and the receptor is human dipeptidyl-peptidase 4 (DPP4).

### Claim 6 (depends on 1)

The multimeric binding molecule of claim 1, wherein the three to twelve binding domains that specifically bind to a human coronavirus bind a human coronavirus structural protein or fragment thereof, wherein the human coronavirus structural protein comprises a nucleocapsid (N) protein, a membrane (M) protein, an envelope (E) protein, a spike (S) protein, any fragment thereof, any subunit thereof, or any combination thereof.

### Claim 7 (depends on 6)

The multimeric binding molecule of claim 6, wherein the three to twelve binding domains specifically bind to the human coronavirus S protein, and wherein the binding domains bind the S protein subunit 1 (S1), the S protein receptor binding domain (RBD), the S protein subunit 2 (S2), the S protein furin cleavage site, or any combination thereof.

### Claim 8 (depends on 1)

The multimeric binding molecule of claim 1, wherein the three to twelve identical binding domains are immunoglobulin antigen binding domains comprising a heavy chain variable region (VH) and a light chain variable region (VL), and wherein each binding unit comprises two heavy chains each comprising a VH and two light chains each comprising a VL.

### Claim 9 (depends on 8)

The multimeric binding molecule of claim 8, wherein the human coronavirus is SARS-CoV-2, wherein the VH and VL comprise six immunoglobulin complementarity determining regions HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the CDRs of an antibody comprising the VH and VL of SEQ ID NO: 88 and SEQ ID NO: 89, SEQ ID NO: 260 and SEQ ID NO: 261, SEQ ID NO: 264 and SEQ ID NO: 265, SEQ ID NO: 266 and SEQ ID NO: 267, SEQ ID NO: 274 and SEQ ID NO: 275, SEQ ID NO: 278, and SEQ ID NO: 279, SEQ ID NO: 280 and SEQ ID NO: 281, SEQ ID NO: 282 and SEQ ID NO: 283, SEQ ID NO: 292 and SEQ ID NO: 293, SEQ ID NO:384 and SEQ ID NO: 385, or SEQ ID NO: 646 and SEQ ID NO: 647, respectively or wherein the VH and VL comprise amino acid sequences at least 80%, at least 85%, at least 90%, at least 95% or 100% identical to the recited VH and VL amino acid sequences, respectively, and wherein the bivalent reference IgG antibody comprising two of the binding domains can neutralize SARS-CoV-2.

### Claim 10 (depends on 8)

The multimeric binding molecule of claim 8, wherein the human coronavirus is SARS-CoV, wherein the VH and VL comprise six immunoglobulin complementarity determining regions HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the CDRs of an antibody comprising the VH and VL of SEQ ID NO: 84 and SEQ ID NO: 85, SEQ ID NO: 260 and SEQ ID NO: 261, SEQ ID NO: 262 and SEQ ID NO: 263, SEQ ID NO: 296 and SEQ ID NO: 297, SEQ ID NO: 628 and SEQ ID NO: 629, SEQ ID NO: 632 and SEQ ID NO: 633, SEQ ID NO: 634 and SEQ ID NO: 635, SEQ ID NO: 636 and SEQ ID NO: 637, SEQ ID NO: 638 and SEQ ID NO: 639, SEQ ID NO: 640 and SEQ ID NO: 641, SEQ ID NO: 642 and SEQ ID NO: 643, or SEQ ID NO: 644 and SEQ ID NO: 645, respectively or wherein the VH and VL comprise amino acid sequences at least 80%, at least 85%, at least 90%, at least 95% or 100% identical to the recited VH and VL amino acid sequences, respectively, and wherein the bivalent reference IgG antibody comprising two of the binding domains can neutralize SARS-CoV.

### Claim 11 (depends on 8)

The multimeric binding molecule of claim 8, wherein the human coronavirus is MERS-CoV, wherein the VH and VL comprise six immunoglobulin complementarity determining regions HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the CDRs of an antibody comprising the VH and VL of SEQ ID NO: 522 and SEQ ID NO: 523, SEQ ID NO: 576 and SEQ ID NO: 577, SEQ ID NO: 610 and SEQ ID NO: 611, SEQ ID NO: 612 and SEQ ID NO: 613, SEQ ID NO: 614 and SEQ ID NO: 615, or SEQ ID NO: 630 and SEQ ID NO: 631, respectively or wherein the VH and VL comprise amino acid sequences at least 80%, at least 85%, at least 90%, at least 95% or 100% identical to the recited VH and VL amino acid sequences, respectively, and wherein the bivalent reference IgG antibody comprising two of the binding domains can neutralize MERS-CoV.

### Claim 12 (depends on 1)

The multimeric binding molecule of claim 1, which can neutralize escape mutants of the bivalent reference IgG antibody comprising two of the binding domains.

### Claim 13 (depends on 1)

The multimeric binding molecule of claim 1, comprising two or four bivalent IgA or IgA-like binding units and a J chain or functional fragment or variant thereof wherein each binding unit comprises two IgA heavy chains each comprising a VH situated amino terminal to the IgA constant region or multimerizing fragment or variant thereof, and two immunoglobulin light chains each comprising a VL situated amino terminal to an immunoglobulin light chain constant region.

### Claim 14 (depends on 13)

The multimeric binding molecule of claim 13, wherein the IgA heavy chain constant regions or multimerizing fragments or variants thereof are human IgA constant regions.

### Claim 15 (depends on 13)

The multimeric binding molecule of claim 13, wherein the J-chain or functional fragment or variant thereof further comprises a heterologous polypeptide, wherein the heterologous polypeptide is directly or indirectly fused to the J-chain or functional fragment or variant thereof.

### Claim 16 (depends on 1)

The multimeric binding molecule of claim 1, comprising five or six bivalent IgM or IgM-like binding units, wherein each binding unit comprises two IgM heavy chain constant regions or multimerizing fragments or variants thereof, wherein each binding unit comprises two IgM heavy chains each comprising a VH situated amino terminal to an IgM constant region or multimerizing fragment or variant thereof, and two immunoglobulin light chains each comprising a VL situated amino terminal to an immunoglobulin light chain constant region.

### Claim 17 (depends on 16)

The multimeric binding molecule of claim 16, wherein the IgM heavy chain constant regions or multimerizing fragments or variants thereof are human IgM constant regions.

### Claim 18 (depends on 16)

The multimeric binding molecule of claim 16 which is pentameric, and further comprises a J-chain or functional fragment or variant thereof.

### Claim 19 (depends on 18)

The multimeric binding molecule of claim 18, wherein the J-chain or functional fragment or variant thereof further comprises a heterologous polypeptide, wherein the heterologous polypeptide is directly or indirectly fused to the J-chain or functional fragment or variant thereof.

### Claim 20 (depends on 1)

A composition comprising the multimeric binding molecule of claim 1; or comprising two or more nonidentical multimeric binding molecules according to claim 1, wherein the two or more multimeric binding molecules bind to different epitopes of a single human coronavirus.

### Claim 21 (depends on 1)

A polynucleotide comprising a nucleic acid sequence that encodes a polypeptide subunit of the binding molecule of claim 1.

### Claim 22 (depends on 21)

A vector comprising the polynucleotide of claim 21.

### Claim 23 (depends on 21)

A host cell comprising the polynucleotide of claim 21, wherein the host cell can express a multimeric binding molecule comprising two to six bivalent binding units or variants or fragments thereof, wherein each binding unit comprises two IgM or IgA heavy chain constant regions or multimerizing fragments or variants thereof, each associated with a binding domain, wherein three to twelve of the binding domains are identical and specifically bind to a human coronavirus, and wherein the binding molecule is more potent than a bivalent reference IgG antibody comprising two of the binding domains that specifically bind to the human coronavirus.

### Claim 24 (depends on 1)

A method for treating or preventing a human coronavirus disease in a subject in need of treatment comprising administering to the subject an effective amount of the multimeric binding molecule of claim 1, wherein the multimeric binding molecule exhibits greater potency than an equivalent amount of a bivalent reference IgG antibody comprising two of the binding domains that specifically bind to the human coronavirus.

### Claim 25 (depends on 24)

The method of claim 24, wherein the human coronavirus disease is severe acute respiratory syndrome (SARS), coronavirus disease 2019 (COVID-19), or Middle East Respiratory Syndrome (MERS).

### Claim 26 (depends on 24)

The method of claim 24, wherein the subject is human.

### Claim 27 (depends on 24)

The method of claim 24, wherein administering comprises intravenous, subcutaneous, intramuscular, intranasal, and/or inhalation administration.
